2022 American Transplant Congress
Development and Validation of a Medication Safety Dashboard in Veteran Transplant Recipients: Preliminary Results of a Multicenter Cluster-Randomized Controlled Clinical Trial
*Purpose: In organ transplant, med errors, adverse drug events, and nonadherence lead to increased healthcare utilization and graft loss. Veterans with transplants are a high-risk…2022 American Transplant Congress
Implementing Clinical Decision Support Tools for Immunosuppressant Drug-Drug Interactions to Prevent Graft Failure
1MAPMG, Mc Lean, VA, 2Kaiser Permanente, Silver Spring, MD, 3MAPMG, Rockville, MA
*Purpose: Immunosuppressant drug-drug interactions can result in immunosuppressant toxicity or subtherapeutic levels causing rejection. If not identified and managed appropriately, these interactions may result in…2022 American Transplant Congress
Impact of Glecaprevir/Pibrentasvir on Tacrolimus Concentration in Solid Organ Transplant Recipients with or without Triazole Antifungal Therapy
*Purpose: Provide guidance on tacrolimus (TAC) dose adjustments during glecaprevir/pibrentasvir (GLE/PIB) initiation and discontinuation in patients on triazole antifungals by comparing changes in TAC concentration-dose…2022 American Transplant Congress
Impact Of Antifungal Prophylaxis Discontinuation On Immunosuppression In Lung Transplant Recipients
Pharmacy, Cleveland Clinic, Cleveland, OH
*Purpose: The purpose of this study is to characterize the impact of antifungal discontinuation on immunosuppressant levels and incidence of acute rejection and fungal infections…2022 American Transplant Congress
Impact Of Nirmatrelvir-Ritonavir On Tacrolimus Concentrations
1University of Rochester Medical Center, Rochester, NY, 2Tampa General Hospital, Tampa, FL
*Purpose: Ritonavir (RTV), a component of the oral antiviral agent nirmatrelvir-RTV (Paxlovid) for COVID-19 infection, increases tacrolimus concentrations through strong competitive inhibition of gastrointestinal and…2022 American Transplant Congress
Phenytoin To Expedite Sirolimus & Tacrolimus Elimination: A Case Report
*Purpose: Sirolimus (SIR), a mammalian target of rapamycin inhibitor (mTORi), may be used with or without a calcineurin inhibitor after heart transplant (HT). The anti-proliferative…2022 American Transplant Congress
New Oral Anticoagulants vs Warfarin in Kidney Transplant
*Purpose: New oral anticoagulants (NOACs) have replaced warfarin due to their similar efficacy and better safety profile in the general population (GP). The risk of…2022 American Transplant Congress
Induction of Tacrolimus Clearance by Steroids Varies by Cyp3a5 Genotype in Kidney Transplant Recipients: A Drug-Drug-Gene Interaction
*Purpose: Tacrolimus (TAC) is the primary immunosuppressant used in organ transplantation. TAC is a substrate for CYP3A4/5. These enzymes are inhibited or induced by multiple…2022 American Transplant Congress
No Grapefruit Juice Interaction with Tacrolimus LCP in Kidney Transplant Recipients
*Purpose: It is well known that grapefruit juice (GFJ) interacts with many medications through an intestinal CYP3A-mediated interaction that does not involve hepatic CYP3A and…2022 American Transplant Congress
Comparison of Cardiovascular Events by Different Types of Lipid-Lowering Drugs in Kidney Transplant Recipients
*Purpose: Lipid-lowering drugs, notably statins, are one of the most widely prescribed drug classes in kidney transplant (KT) recipients. These drugs have substantially different mechanisms…
- 1
- 2
- 3
- …
- 7
- Next Page »